Watch out Pfizer, Novartis’ LEE011 bags quick OK for frontline use against breast cancer
Novartis picked up a key regulatory win today, gaining the FDA’s quick OK for LEE011, its CDK 4/6 drug now approved as a frontline therapy for postmenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative advanced or metastatic breast cancer in combination with any aromatase inhibitor.
The drug, also known as ribociclib, hits the market as Kisqali with peak sales estimates of around $2.5 billion a year, giving the pharma giant a clear shot at a new blockbuster franchise.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.